Cancure
  • Home
  • About
    • Vision
    • Board & Management
    • Scientific Advisors
  • Cancer
    • Current Treatments
    • Market
  • Therapies
    • Genvax – lead candidate CNC118
    • Galectin – lead candidate CNC225
    • Mitocans – lead candidate CNC332
    • Combination Therapy
    • Genvax vs. CAR-T
    • Development Program
    • References
  • Investors
    • Investors Snapshot
    • News
    • Public Documents
  • Contact
  • Glossary of Terms
  • Search
  • Menu Menu
Genvax
Galectin
Mitocans
Mitocans

THERAPIES

Cancure will develop three distinct drug candidates – Genvax platform, lead candidate CNC118; Galectin program, lead candidate CNC225; Mitocans program, lead candidate CNC332  – into Ph2, Ph1, and Ph1 clinical trials, respectively. These technologies are collectively supported by more than 75 peer-reviewed articles in scientific journals and protected by six patent families.

Both Genvax and Galectin enhance the immune response to fight cancer, positioning these programs at the cutting edge of immuno-oncology. Some immuno-oncology drug candidates are now yielding unprecedented patient response rates in late-stage clinical trials. Cancure’s third program, Mitocans, is a targeted therapy that disrupts the energy-producing machinery in the mitochondria of cancer cells to induce metabolic crisis and natural death (apoptosis) of these cells.

  • Genvax – lead candidate CNC118
  • Galectin – lead candidate CNC225
  • Mitocans – lead candidate CNC332
  • Combination Therapy
  • Genvax vs. CAR-T
  • Development Program
  • References

NEWS

  • NousCom receives $49M to trial off-the-shelf cancer vaccine
  • AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans
  • Incyte pays MacroGenics $150M for PD-1 inhibitor
  • Gilead buys CAR-T developer Kite Pharma for $12B

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2021 All rights reserved.
  • Twitter
  • Dribbble
Scroll to top